Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
mild asthma; lung allergic issues; This non-serious case was reported by a consumer and described the occurrence of asthma in a 68-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Concurrent medical conditions included irritable bowel syndrome and restless legs syndrome. Concomitant products included pregabalina, dicycloverine hydrochloride (Dicyclomine) and ropinirole hydrochloride (Ropinirole). On 17-SEP-2025, the patient received Arexvy. On 18-SEP-2025, 1 days after receiving Arexvy, the patient experienced asthma (Verbatim: mild asthma) and multiple allergies (Verbatim: lung allergic issues). The patient was treated with fluticasone propionate, salmeterol xinafoate (Wixela Inhub), prednisone acetate (Prednisone) and amoxicillin;clavulanic acid. The outcome of the asthma and multiple allergies were not resolved. It was unknown if the reporter considered the asthma and multiple allergies to be related to Arexvy. It was unknown if the company considered the asthma and multiple allergies to be related to Arexvy. Additional Information: GSK Receipt Date: 26-SEP-2025 The patient had not experienced any asthma issues until 20 hours after receiving the vaccine. Patient was taking medications such as Voquenza and Exitimbe. The batch number was not provided, and we are unable to contact the reporter.
Irritable bowel syndrome; Restless legs syndrome
Pregabalina; Dicyclomine; Ropinirole